Cystic Fibrosis

• Cystic Fibrosis - Oct 02, 2025
• Inhaled Drugs for Cystic Fibrosis - Dec 02, 2021
• Cystic Fibrosis - Jun 03, 2021

• Cystic Fibrosis Class Update - Jun 04, 2020
• Cystic Fibrosis - Sep 26, 2019
• Oral Cystic Fibrosis Modulators - Sep 27, 2018
• Oral Cystic Fibrosis Modulators - Jul 26, 2018
• Oral Cystic Fibrosis Modulators - Nov 17, 2016
• Inhaled Drugs for Cystic Fibrosis - Jan 28, 2016
• Inhaled Medications for Cystic Fibrosis - May 28, 2015
• Cystic Fibrosis Abbreviated Class Update - May 29, 2014
• Cystic Fibrosis - Inhaled Antibiotics Class Update - Mar 27, 2014
• Abbreviated Class Review: Fat-Soluble Vitamins for the Use of Cystic Fybrosis - May 30, 2013
• Abbreviated Drug Evaluation: Hypertonic Saline Inhalation for Cystic Fybrosis - Sep 27, 2012
• Abbreviated Class Review: Inhaled Antibiotics and Dornase Alfa for Cystic Fibrosis - Aug 30, 2012

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.